EU/3/18/2041

Table of contents

About

On 31 July 2018, orphan designation (EU/3/18/2041) was granted by the European Commission to Ionis USA Ltd, United Kingdom, for 2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA for the treatment of behavioural variant frontotemporal dementia.

The sponsorship was transferred to Biogen Netherlands B.V., The Netherlands in October 2020.

Key facts

Active substance
2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA
Disease / condition
treatment of behavioural variant frontotemporal dementia
Date of first decision
31/07/2018
Outcome
Positive
EU designation number
EU/3/18/2041

Sponsor's contact details

Biogen Netherlands B.V.
Prins Mauritslaan 13-19
1171 LP Badhoevedorp Noord-Holland
Netherlands
E-mail: ukreception@biogen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating